Baxdela (Delafloxacin Meglumine) Patent Expiration, LOE Window & CMS Spending

Baxdela (Delafloxacin Meglumine) by Melinta Subsidiary: FDA Orange Book core substance LOE 2031-06-19, 0 AB generics, $296K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMelinta Subsidiary
FDA Application & PathwayN208610 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-06-19
Last Listed Patent or Exclusivity Date2031-06-19
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$296K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$296K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel